Louisiana lawmakers are setting the stage for a high-stakes budget and health fight as they advance a bill that could open Medicaid to costly but wildly popular GLP-1 weight loss drugs. If it becomes law, thousands of Medicaid enrollees could qualify for prescriptions like Wegovy and Zepbound starting Jan. 1, 2027.
Senate Bill 433, sponsored by Sen. Gerald Boudreaux, would require managed care plans in the state Medicaid program to cover FDA-approved weight loss medications for adults who either have a body mass index of 30 or higher with at least one related comorbidity or a BMI of 35 or greater. The proposal is written to take effect on Jan. 1, 2027. The bill's page on the Louisiana Legislature website shows it cleared the Senate Health and Welfare Committee and was scheduled for a Senate floor vote on April 20, 2026, according to Louisiana Legislature.
At a committee hearing, Louisiana Medicaid director Seth Gold told lawmakers the drugs cost about $16,000 per patient per year and that roughly 145,000 enrollees would meet the bill's eligibility criteria. Gold's office estimated that expanded coverage could cost roughly $189 million for the first six months of 2027 and about $296 million for the 2027-28 fiscal year, with tens of millions of that total coming from state funds, as reported by New Orleans CityBusiness.
State officials said they will apply to participate in a federal GLP-1 savings program negotiated by the Trump administration that could sharply reduce Louisiana's tab. Medicaid officials suggested the state share might fall to roughly $7 million for the first half of 2027 and about $11 million for the following fiscal year under that deal. The White House agreement with manufacturers to expand coverage and lower prices was detailed by AP News.
The national picture is far from settled. Research from KFF shows several states that briefly covered GLP-1s have since rolled back benefits under budget pressure, leaving coverage uneven across the country and underscoring the affordability concerns raised in the Louisiana debate.
What the Bill Would Require
According to the bill's fiscal note, managed care organizations would be required to cover the drugs, and prior authorization would be limited to verifying that patients meet eligibility criteria. Initial authorizations would be capped at six months, with continued coverage dependent on documented clinical improvement. The Legislative Fiscal Office also warned that the measure could increase state general fund and federal expenditures and deferred to the Department of Health for detailed cost estimates, per the Legislative Fiscal Office.
Supporters and Critics
Supporters, including the American Diabetes Association, argue that the drugs treat a chronic, relapsing disease and can help prevent costly complications down the line. "Importantly, obesity is not simply a matter of personal choice or willpower," ADA lobbyist Douglas Dunsavage told lawmakers. Louisiana Health Secretary Bruce Greenstein called the medicines "a blockbuster" and said the state will seek the federal discount, as reported by New Orleans CityBusiness.
The looming Senate floor vote will test how far lawmakers are willing to stretch Medicaid dollars to expand access to expensive new treatments. They are staring down a familiar tradeoff: potential long-term savings from preventing chronic disease versus immediate budget pressure that could force cuts elsewhere.
